LimmaTech Biologics AG
Michael Reindl is a seasoned professional with extensive experience in clinical development and operations within the biopharmaceutical industry. Currently serving as Group Lead for Clinical Development/Clinical Operations at LimmaTech Biologics AG, Michael has previously held senior leadership roles, including Senior Director and Head EU Clinical Operations at Arena Pharmaceuticals, Regional Head of Global Clinical Operations at Merck Group, and Director of Clinical Operations at CureVac AG. With a background that encompasses managing large-scale clinical trials across various phases and therapeutic areas, including gastroenterology, oncology, and infectious diseases, Michael demonstrates strong expertise in clinical trial management, cross-functional coordination, and team leadership. Michael holds a Ph.D. in Toxicology from Johannes Gutenberg University Mainz and a Diploma in Chemistry from The Julius Maximilians University of Würzburg.
This person is not in any teams
This person is not in any offices
LimmaTech Biologics AG
LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.